INMUNE BIO INC. - COMMON STOCK

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

12 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

10 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

28 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

10 Dec 2024 07:00:01 By Nasdaq GlobeNewswire

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

04 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

13 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

31 Oct 2024 15:05:51 By Nasdaq GlobeNewswire

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

28 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

24 Oct 2024 14:03:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

24 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

11 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

26 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

INmune Bio Announces $13.0 Million Registered Direct Offering

13 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

01 Aug 2024 15:05:39 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

23 Jul 2024 07:45:00 By Nasdaq GlobeNewswire